Thalidomide 100 mg was given at night for two weeks, and thereafter a maintenance regimen of 100 mg every fifth day was followed. Treatment was stopped after six weeks in cases 1, 4, and 5 but was given continuously for three to six months in cases 2, 3, 6, and 7. The mouth ulcers healed rapidly in all seven patients. In three cases treatment was initially associated with drowsiness, and the dose was reduced to 50 mg. In the patients who received only six weeks' maintenance treatment the ulcers recurred between one and five months after the end of treatment. In the four patients whose treatment was continued no relapses were noticed. No serious adverse effects were seen, and in particular no signs of peripheral neuropathy, during follow up of between three and six months. Two patients took zidovudine before thalidomide and four others subsequently took it with no adverse interactions. No appreciable changes in OKT4 cell count were seen during treatment with thalidomide (table) .
Comment
There is no diagnostic test for aphthous ulcers, but these ulcers all had the typical punched out appearances of aphthous ulcers and responded dramatically to thalidomide after failing to respond to conventional treatment.
Thalidomide has been shown to have a beneficial effect in several conditions such as erythema nodosum leprosum, Behqet's disease, actinic prurigo, and graft versus host reactions. The mechanism is obscure, although immunomodulation has been suggested.5 Thalidomide seems to have a place in the treatment of resistant aphthous ulceration in patients positive for HIV antibody, but its use in women of childbearing age is totally contraindicated. At present supplies of thalidomide in the United Kingdom are limited, but with its increasing range of therapeutic uses it should become more widely available. 
